Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast
AssigneeCelgene International II SÀRL
InventorsPeter H. Schafer, Matthew William Burnell Trotter
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for predicting the clinical sensitivity of an inflammatory disease (e.g., ankylosing spondylitis) and a subject's response to treatment with apremilast using the level of a biomarker (e.g., MCP1). Also provided herein are methods for treating an inflammatory disease.
Claims19
A method of identifying a subject having ankylosing spondylitis who is likely to be responsive to a treatment with apremilast, predicting the responsiveness of a subject having or suspected of having ankylosing spondylitis to a treatment with apremilast, or treating a subject having ankylosing spondylitis, comprising:
- (a) identifying the subject having ankylosing spondylitis that may be responsive to a treatment with apremilast, comprising:
- i. obtaining a sample from the subject;
- ii. measuring the level of MCP1 in the sample;
- and
- iii. diagnosing the subject as being likely to be responsive to apremilast if the level of MCP1 in the sample is lower than a threshold level of MCP1, and
- (b) administering the subject a therapeutically effective amount of apremilast if the subject is identified as being likely to be responsive to treatment with apremilast.
Dependencies are inferred from the claim text.